PMID- 20385003
OWN - NLM
STAT- MEDLINE
DCOM- 20100709
LR  - 20211020
IS  - 1471-2172 (Electronic)
IS  - 1471-2172 (Linking)
VI  - 11
DP  - 2010 Apr 12
TI  - Tumor infiltrating lymphocytes: an intriguing player in the survival of 
      colorectal cancer patients.
PG  - 19
LID - 10.1186/1471-2172-11-19 [doi]
AB  - BACKGROUND: There is growing evidence that both local and systemic inflammatory 
      responses play an important role in the progression of a variety of solid tumors. 
      Colorectal cancer results from the cumulative effect of sequential genetic 
      alterations, leading to the expression of tumor associated antigens possibly 
      inducing a cellular anti-tumor immune response. It is well recognized that 
      cytotoxic lymphocytes constitute one of the most important effector mechanisms of 
      anti-tumor-immunity. However, their potential prognostic influence in colorectal 
      cancer remains controversial. Aim of the study was to examine infiltration of 
      CD3+ and CD8+ lymphocytes in colorectal cancer and their prognostic 
      potential.Two-hundred-fifteen colorectal cancer cases, previously analyzed for 
      microsatellite instability (MSI), were selected for immunohistochemical detection 
      of CD3+, CD8+ infiltration and the expression of granzyme B. Prognostic relevance 
      was assessed by survival analysis. RESULTS: Strong correlations were found 
      between the infiltration of lymphocytes and several clinicopathological 
      variables. Survival analysis revealed that intra-epithelial infiltration of CD3+ 
      and CD8+ T lymphocytes and stromal infiltration of CD3+ lymphocytes had a major 
      impact on the patients' overall survival in the univariate analysis, however 
      independent of their association with MSI-status. In addition, it was also 
      demonstrated that there was an important disease specific survival advantage for 
      patients with microsatellite stable (MSS) tumors containing intraepithelial CD8+ 
      tumor infiltrating lymphocytes. When samples were analyzed for colon cancer and 
      rectal cancer separately, the results of the overall population were confirmed in 
      colon cancer only. When entered into a multiple Cox regression analysis adjusting 
      for other possible important confounding factors, the strong impact of lymphocyte 
      infiltration on overall survival was not maintained. Only early stage and young 
      age (borderline significant for overall population only) were associated with a 
      better overall survival (early disease with disease-free survival also). 
      CONCLUSIONS: In conclusion our results suggest a role for infiltrating CD3+ and 
      CD8+ T lymphocytes in colorectal cancer whereby tumor infiltration could reflect 
      a general principle of antitumor immunity, irrespective of the MSI-status.
FAU - Deschoolmeester, Vanessa
AU  - Deschoolmeester V
AD  - Laboratory of Cancer Research and Clinical Oncology, Department of Medical 
      Oncology, University of Antwerp (UA/UZA), Wilrijk, Belgium. 
      vanessa.deschoolmeester@ua.ac.be
FAU - Baay, Marc
AU  - Baay M
FAU - Van Marck, Eric
AU  - Van Marck E
FAU - Weyler, Joost
AU  - Weyler J
FAU - Vermeulen, Peter
AU  - Vermeulen P
FAU - Lardon, Filip
AU  - Lardon F
FAU - Vermorken, Jan B
AU  - Vermorken JB
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20100412
PL  - England
TA  - BMC Immunol
JT  - BMC immunology
JID - 100966980
RN  - 0 (Biomarkers, Tumor)
SB  - IM
MH  - Aged
MH  - Biomarkers, Tumor/*immunology
MH  - CD8-Positive T-Lymphocytes/immunology/metabolism/pathology
MH  - Colorectal Neoplasms/*immunology/*mortality/pathology
MH  - Disease-Free Survival
MH  - Female
MH  - Humans
MH  - Immunohistochemistry
MH  - Kaplan-Meier Estimate
MH  - Lymphocytes, Tumor-Infiltrating/*immunology/metabolism/pathology
MH  - Male
MH  - Microsatellite Instability
MH  - Middle Aged
PMC - PMC2864219
EDAT- 2010/04/14 06:00
MHDA- 2010/07/10 06:00
PMCR- 2010/04/12
CRDT- 2010/04/14 06:00
PHST- 2009/09/25 00:00 [received]
PHST- 2010/04/12 00:00 [accepted]
PHST- 2010/04/14 06:00 [entrez]
PHST- 2010/04/14 06:00 [pubmed]
PHST- 2010/07/10 06:00 [medline]
PHST- 2010/04/12 00:00 [pmc-release]
AID - 1471-2172-11-19 [pii]
AID - 10.1186/1471-2172-11-19 [doi]
PST - epublish
SO  - BMC Immunol. 2010 Apr 12;11:19. doi: 10.1186/1471-2172-11-19.